Does semaglutide cause cancer in people?

Human studies have not established that semaglutide causes cancer. A 2026 analysis of 148 randomized trials found no overall cancer increase across the GLP-1 drug family, but that does not prove zero risk for every cancer or for decades of use. The thyroid warning remains because tumors occurred in rodents and the relevance to people is unknown.

Why does semaglutide have a thyroid cancer warning?

The warning comes from thyroid C-cell tumors in rats and mice exposed to semaglutide. C cells make the hormone calcitonin, and medullary thyroid cancer begins in those cells. The human relevance remains unknown. Wegovy and Ozempic labels exclude people with a personal or family history of that cancer, or with MEN 2, an inherited tumor syndrome.

Does semaglutide cause pancreatic cancer?

Available analyses have not established an increased pancreatic cancer risk with semaglutide. Pancreatitis, which means pancreatic inflammation, is a separate labeled concern and is not itself cancer. Cancer events have been uncommon in trials, and much of the follow-up is too short to settle long-term risk. A previous pancreatic illness still matters in the prescribing review.

Can semaglutide prevent cancer?

Cancer prevention has not been established. Some studies of medical records found lower cancer rates among GLP-1 users, but results depended on the comparison treatment. In the 2024 study of 13 obesity-associated cancers, reductions appeared against insulin, not metformin. These findings support further investigation; they do not establish semaglutide as a cancer-prevention treatment.

Does every family history of thyroid cancer rule out semaglutide?

The exact type matters: the labels specifically name a personal or family history of medullary thyroid carcinoma, along with MEN 2 in the patient. Other thyroid cancers and common thyroid conditions are not interchangeable with those diagnoses. An uncertain family diagnosis needs clarification during the medical review rather than an assumption that it is either harmless or automatically disqualifying.

Does Semaglutide Cause Cancer? What Studies Show

Human studies have not established that semaglutide causes cancer. The thyroid warning comes from tumors found in rats and mice; whether the same thing happens in people remains unknown. Most human findings have not shown an overall cancer increase, but they cannot settle the risk over decades.

So, does semaglutide cause cancer? The evidence supports a careful answer, not a promise of zero risk. The kind of cancer, the comparison group and the length of follow-up all matter.

Does semaglutide cause cancer in humans?

The broadest recent trial evidence found no overall increase. Semaglutide belongs to the GLP-1 family, medicines that copy a gut hormone involved in blood sugar and appetite. Studies often combine several medicines in that family, so a result for the group isn't automatically a result for semaglutide alone.

As of September 10, 2026, the day this article was written, a Scientific Reports analysis published August 27, 2026 had pooled 148 randomized trials, studies that assign treatment by chance, involving 168,875 participants. Overall cancer risk was similar between groups: the relative risk, a comparison between treatment and control, was 0.99, where 1 means no difference. Its uncertainty range was 0.92–1.05.

That is useful evidence against an overall increase during the studies. It doesn't establish lifetime safety or show that semaglutide prevents cancer. The authors also cautioned against choosing these medicines for cancer prevention.

Why the thyroid warning is still on the label

A boxed warning is the most prominent warning in U.S. prescription information. Semaglutide's concerns thyroid C cells, cells that make a hormone called calcitonin. In lifetime studies, treated rodents, meaning rats and mice, developed tumors in these cells.

As of September 10, 2026, the day this article was written, the Wegovy record on DailyMed carried “Revised: 6/2026”; the FDA-posted label prints “Revised: 06/2026.” Both retain the warning and say its relevance to humans is unknown. The Ozempic label, revised May 2026, carries the same concern.

The labels rule out use with a personal or family history of medullary thyroid carcinoma, or MTC, a cancer arising in those C cells. They also rule out use in someone with multiple endocrine neoplasia type 2, or MEN 2, an inherited condition that raises the risk of certain gland tumors. These are specific exclusions, not a statement that all thyroid problems are alike.

What the human thyroid studies found

A large Scandinavian study offers some reassurance within a limited window. Pasternak and colleagues, BMJ, 2024, compared 145,410 people starting GLP-1 medicines with 291,667 starting another diabetes drug class.

Thyroid cancer occurred at about 1.3 versus 1.5 cases per 10,000 people followed for a year. Average follow-up in the GLP-1 group was 3.9 years, and the researchers found no increased overall thyroid cancer risk. The estimate for the rare medullary type was too uncertain to rule out an increase.

Other findings complicate the picture. Brito and colleagues, JAMA Otolaryngology–Head & Neck Surgery, 2025, found more thyroid cancer diagnoses during the first year after starting a GLP-1 medicine, though their main overall result was not statistically clear. They suggested extra testing could help explain the early finding. Medical-record studies cannot establish cause on their own.

Tirzepatide is another medicine a provider may compare for weight management, but its January 2026 Zepbound label also names MTC and MEN 2. The separate guide to tirzepatide and thyroid cancer explains that warning.

Why some studies report lower cancer rates

The comparison matters. In Wang and colleagues' JAMA Network Open study, 2024, researchers examined records from 1.65 million adults with type 2 diabetes. GLP-1 use was associated with lower risk of 10 of 13 cancers linked to excess body fat when compared with insulin.

Against metformin, another diabetes medicine, no cancer showed a statistically clear reduction. Kidney cancer risk was higher in that comparison. Neither finding proves that the medicine caused the difference, and the study covered the drug family rather than semaglutide alone.

As of September 10, 2026, the day this article was written, Hsu and colleagues' Annals of Oncology study, published online June 7, 2026, had added evidence in adults with obesity who did not have diabetes. It matched 80,899 GLP-1 users with 80,899 people receiving diet or exercise counseling and found lower combined cancer incidence over a median follow-up, the middle value, of two years. Matching makes groups more comparable; it cannot remove every difference or turn an association into proof of prevention.

Semaglutide and pancreatic cancer are a separate question

Pancreatitis means inflammation of the pancreas; it is not pancreatic cancer. Semaglutide has a pancreatitis warning, but that warning does not establish that the medicine causes cancer. The semaglutide and pancreatitis guide covers symptoms and the clinical review.

A 2023 semaglutide review in Diabetes & Metabolic Syndrome found no statistically clear pancreatic cancer increase, although cases were scarce and estimates uncertain.

As of September 10, 2026, the day this article was written, a July 7, 2026 review in npj Gut and Liver reported that three analyses combining randomized trials had found no increase in pancreatic cancer with GLP-1 medicines. It also emphasized that most follow-up was short for a cancer that can take many years to develop. Reports submitted after a medicine reaches the market can flag a concern, but cannot establish its cause on their own.

The separate eye concern, NAION, involves injury from reduced blood flow to the nerve carrying sight; it is not cancer.

What this means for a compounded prescription

Through Promise, semaglutide is dispensed as a compounded medication, prepared by a pharmacy for an individual prescription, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. As the FDA explains, compounded drugs do not undergo its review for safety, effectiveness or quality before marketing.

A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision is between the patient and the doctor. The published cancer findings do not establish identical outcomes for every compounded preparation, and compounding does not remove the need to review cancer history.

What the provider needs to know

The review starts with the exact personal and family cancer diagnoses, especially MTC or MEN 2, and any unexplained neck lump, persistent hoarseness or swallowing difficulty. A cancer history deserves an individual discussion, including current treatment and the reason semaglutide is being considered.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The useful next step is a review of the person's actual history, with the evidence and its limits both on the table.